OHSU study: Telehealth builds autonomy, trust in treating addiction

Health Care , Research , Addiction Medicine
Telehealth and opioids
Telehealth and opioids
A medical professional is on a telehealth screen while the patient is at home, holding a bottle of opioids. A new study from Oregon Health & Science University suggests that telehealth may reduce stigma and barriers for people seeking addiction treatment amid the ongoing opioid epidemic. (Getty Images)
A new study from Oregon Health & Science University suggests that telehealth may reduce stigma and barriers for people seeking addiction treatment amid the ongoing opioid epidemic. (Getty Images)

Even as the nation’s opioid epidemic continues to ravage families and communities nationwide — with more than 100,000 Americans dying of drug overdoses each year — stigma remains a barrier for many people accessing treatment for addiction.

A new study from Oregon Health & Science University suggests telehealth may be an important antidote to overcoming stigma and reducing barriers for people seeking out the treatment they need.

Find more on OHSU’s leadership in addiction medicine.

The study, published recently in the Harm Reduction Journal, compiled in-depth interviews with 30 people treated for substance use disorder at OHSU from March of 2020 to December of 2021. Due to the COVID-19 pandemic, federal regulations eased the ability of people to enter treatment through virtual visits during that time, as opposed to having to visit a clinic in person.

Ximena A. Levander, M.D., has long wavy, dark hair, and is wearing eyeglasses, smiling against a gray background.
Ximena A. Levander, M.D. (OHSU)

“You feel like you’re being watched or judged by everyone, and telehealth can reduce that sense whether it’s real or perceived,” said senior author Ximena Levander, M.D., assistant professor of medicine (general internal medicine and geriatrics) in the OHSU School of Medicine. “Telehealth can lower that barrier.”

Patients reported that they appreciated the implicit sense of autonomy and trust involved in being able to connect with clinicians through video or telephone visits. Patients received prescriptions for buprenorphine, a partial opioid receptor agonist that inhibits opioid withdrawal symptoms.

Co-authors identified four themes among patients interviewed in the study:

“Our results support a more individualized approach to care, whereby patients may choose whether they receive care in person or via telehealth,” the authors write. “Given that aspects of both telehealth and in-person treatment left some participants feeling judged by their clinicians, our findings also highlight the need to further explore how clinicians perpetuate stigma through telehealth-based programs, and how training and clinical guidelines could mediate this.”

In addition to Levander, OHSU co-authors included Jessica V. Couch, Mackenzie Whitcomb, M.D., Bradley M. Buchheit, M.D., David A. Dorr, M.D., Darren J. Malinoski, M.D., Todd Korthuis, M.D., and Sarah S. Ono, Ph.D.

The research was supported by the Agency for Healthcare Research and Quality, grant award K12 HS026370, the National Institute on Drug Abuse of the National Institutes of Health, grant awards UH3DA044831, UG1DA015815 and National Center For Advancing Translational Sciences of the National Institutes of Health grant award UL1TR002369; and a seed award through the OHSU Division of General Internal Medicine’s Section of Addiction Medicine.


Erik Robinson
Senior Media Relations Specialist
503-494-8231